Videos

Kidney cancer expert, Dr Thomas E. Hutson, shares insight on managing adverse events resulting from combination therapy in RCC.

An expert discusses the most common reasons his patients ask him about medical marijuana.

Current barriers that impact patient access to comprehensive biomarker testing in the community and efforts underway to help advocate for increased accessibility to molecular assays moving forward.

Resources available to support patients and community oncologists who are interested in learning more and gaining access to comprehensive biomarker testing.

The vaccine immune response monitoring platform can identify weak responses in patients with cancer and help determine the potential need for a booster shot.

Thomas E. Hutson, DO, PharmD, discusses his approach to determining the optimal initial therapy for a patient with RCC.

Urologic oncology expert, Dr Thomas E. Hutson, reviews additional agents and clinical trials in the pipeline for the treatment of RCC.

View the full CURE® Educated Patient® Webinar: Gastrointestinal Stromal Tumor (GIST).

Cancer patients, Deborah and George, reflect on their emotions while waiting to receive back results from biomarker testing and explain what it was like processing the information delivered by their test results as presented by their oncologists.

George Labonte explains what it was like receiving a diagnosis of medullary thyroid cancer and describes his experience being recommended for biomarker testing and concerns surrounding testing for germline mutations.

An expert in kidney cancer reviews the phase 3 CLEAR trial for frontline metastatic renal cell carcinoma.

Dr Thomas E. Hutson shares insight on recent advances for the treatment of RCC including the role of and VEGF inhibitors, immune therapy, and mTOR inhibitors.

Do you keep your job? Your friends? One cancer survivor discusses her decisions after being told her non-Hodgkin lymphoma was in remission.

On behalf of AiM at Melanoma, Drs. Jeffrey Farma and Sunandana Chandra discuss current and future treatment options for melanoma, including a rare subtype.

The basics of uveal melanoma

Discussing emerging therapies in melanoma

Understanding Immune-Modulating Antibodies

Updates in adjuvant and neoadjuvant therapy in melanoma

Results demonstrating the efficacy of Bavencio highlight the importance of incorporating recent clinical trial successes into the treatment conversation.

Deborah Kimmel describes the symptoms that led to a diagnosis of advanced non–small cell lung cancer and explains her journey to connecting with Dr Benjamin Levy and undergoing molecular testing.

The rationale for testing 2 patients with cancer, Deborah and George, with molecular testing prior to managing their cases with novel therapy.

Thomas E. Hutson, DO, PharmD, discusses the historic and current goals of therapy for the treatment of RCC.

Kidney cancer expert, Dr Thomas E. Hutson, comments on treatment approaches for the management of renal cell carcinoma.

Anna C. Pavlick, D.O., describes the various challenges health care providers may face when treating patients with locally advanced basal cell carcinoma (laBCC).

Insights into cemiplimab treatment monitoring and management in locally advanced basal cell carcinoma (laBCC).

An expert discusses treatment options available for patients with locally advanced basal cell carcinoma (laBCC) who don’t respond or are intolerant to the first-line therapy option.

View the full CURE® Educated Patient® Webinar: Biomarkers, Why Genomic Testing Matters on demand.

According to an expert from The University of Texas MD Anderson Cancer Center, patient enrollment in clinical trials that involve genomic testing are important in progressing research in their cancer types.

Drs Benjamin Levy and Lori J Wirth describe the differences between germline and somatic mutations, explain how these are detected and used to guide treatment for lung and thyroid cancer, and comment on counseling patients about concerns of hereditary findings.

Benjamin Levy, MD, briefly describes the difference between driver mutations and immunotherapy biomarkers in non–small cell lung cancer and explains how decisions for immunotherapy or targeted therapy are made based on results of molecular assays.